Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Related Citations for PubMed (Select 23636143)

1.

Personalized cancer treatment and the myth of KRAS wild-type colon tumors.

Parsons BL, Myers MB.

Discov Med. 2013 Apr;15(83):259-67. Review.

2.

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.

3.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

4.

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA.

J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4. Review.

PMID:
20921461
5.

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy.

Chang DZ, Kumar V, Ma Y, Li K, Kopetz S.

J Hematol Oncol. 2009 Apr 22;2:18. doi: 10.1186/1756-8722-2-18. Review.

6.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.

J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2.

7.

KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine.

Wang HL, Lopategui J, Amin MB, Patterson SD.

Adv Anat Pathol. 2010 Jan;17(1):23-32. doi: 10.1097/PAP.0b013e3181c6962f. Review.

PMID:
20032635
8.

Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T.

Cancer Res. 2011 Mar 1;71(5):1520-5. doi: 10.1158/0008-5472.CAN-10-2817. Epub 2010 Dec 30.

9.

Down-regulation of epidermal growth factor receptor by selective expansion of a 5'-end regulatory dinucleotide repeat in colon cancer with microsatellite instability.

Baranovskaya S, Martin Y, Alonso S, Pisarchuk KL, Falchetti M, Dai Y, Khaldoyanidi S, Krajewski S, Novikova I, Sidorenko YS, Perucho M, Malkhosyan SR.

Clin Cancer Res. 2009 Jul 15;15(14):4531-7. doi: 10.1158/1078-0432.CCR-08-1282. Epub 2009 Jul 7.

10.

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.

Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA.

Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006. Review.

PMID:
21200037
11.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

12.

KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.

Siddiqui AD, Piperdi B.

Ann Surg Oncol. 2010 Apr;17(4):1168-76. doi: 10.1245/s10434-009-0811-z. Epub 2009 Nov 20. Review.

13.

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.

Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S.

PLoS One. 2009 Oct 2;4(10):e7287. doi: 10.1371/journal.pone.0007287.

14.

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.

Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, Baldus SE, Schaefer KL.

J Cancer Res Clin Oncol. 2013 Feb;139(2):201-9. doi: 10.1007/s00432-012-1319-7. Epub 2012 Sep 27.

PMID:
23015072
15.

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.

Sánchez-Muñoz A, Gallego E, de Luque V, Pérez-Rivas LG, Vicioso L, Ribelles N, Lozano J, Alba E.

BMC Cancer. 2010 Apr 13;10:136. doi: 10.1186/1471-2407-10-136.

16.

The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.

Stintzing S, Heinemann V, Moosmann N, Hiddemann W, Jung A, Kirchner T.

Dtsch Arztebl Int. 2009 Mar;106(12):202-6. doi: 10.3238/arztebl.2009.0202. Epub 2009 Mar 20. Review.

17.

Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.

Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, Plukker JT.

Am J Gastroenterol. 2000 Oct;95(10):2953-7.

PMID:
11051374
18.

Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis.

Lin AY, Buckley NS, Lu AT, Kouzminova NB, Salpeter SR.

Clin Colorectal Cancer. 2011 Mar 1;10(1):63-9. doi: 10.3816/CCC.2011.n.009. Review.

PMID:
21609938
19.

KRAS mutation testing in colorectal cancer.

Plesec TP, Hunt JL.

Adv Anat Pathol. 2009 Jul;16(4):196-203. doi: 10.1097/PAP.0b013e3181a9d4ed. Review.

PMID:
19546608
20.

A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.

Adelstein BA, Dobbins TA, Harris CA, Marschner IC, Ward RL.

Eur J Cancer. 2011 Jun;47(9):1343-54. doi: 10.1016/j.ejca.2011.03.031. Epub 2011 May 5. Review.

PMID:
21550229
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk